VJOncology Podcast

In this week’s VJOncology podcast, the first of 2026, we bring you key updates in the use of artificial intelligence (AI) in oncology and how it will impact clinicians and patients alike. Join renowned experts Anita Grigoriadis, PhD, King’s College London, London, UK, Rosalind Picard, ScD, MIT Media Lab, Cambridge, MA, Jana Lipkova, PhD, University of California, Irvine, CA, and Roberto Salgado, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia as they comment on how to increase AI literacy for oncologists, identifying patients with high-risk lobular breast cancer with AI, and more.

In this episode of the VJOncology Podcast, we bring you key highlights from the San Antonio Breast Cancer Symposium 2025 (SABCS 2025). This curated episode features expert insights into practice-changing data across HER2-positive metastatic disease, hormone receptor–positive early breast cancer, and the growing role of artificial intelligence in risk stratification. Leading investigators discuss advances in targeted therapies, endocrine treatment optimization, and AI-driven tools that may refine prognostic assessment and clinical decision-making in breast cancer.

In this week’s VJOncology podcast, we will be covering highlights from ESMO 2025 in Berlin, Germany. Gain expert insights in the field of genitourinary cancers, including highly-anticipated trial results, emerging biomarkers in kidney cancer, and the evolving role of radionuclides in  prostate cancer. Join renowned speakers Andrea Necchi, MD, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, Sara Coca Membribes, MD, Barts Health NHS Trust, London, UK, Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, Paul Nguyen, MD, MBA, Dana-Farber Cancer Institute, Boston, MA, as they discuss trials such as GDFather-NEO, CALYPSO, and more.

In this week’s VJOncology podcast, we have the pleasure to bring you key updates in gastrointestinal cancer at ESMO 2025, which we attended live in Berlin. Join esteemed experts Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, Michele Reni, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, and Anwaar Saeed, MD, University of Pittsburgh, Pittsburgh, PA, as they discuss ground-breaking trials such as FORTITUDE-101, CASSANDRA, STELLAR-303, and more.

In this episode of the VJOncology Podcast, we bring you four standout interviews from ESMO 2025 that are reshaping the way we think about lung cancer. From antibody-drug conjugates and bispecific T-cell engagers through novel HER2-targeted TKIs to tumour-immune microenvironment biomarkers, the treatment paradigm is evolving rapidly.

Join us as we explore findings from the Phase III OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutant non-small-cell lung cancer (NSCLC) post-TKI progression, safety analysis of DeLLphi-304: tarlatamab vs standard chemo in small-cell lung cancer (SCLC), the first-line Beamion LUNG-1 experience of zongertinib in advanced HER2-mutant NSCLC and biomarker...

In this week’s podcast from VJOncology, leading experts share key insights from the 44th Congress of the European Society of Surgical Oncology (ESSO 44), held in Gothenburg, Sweden. The meeting brought together global specialists to discuss innovations in cancer surgery, including artificial intelligence, robotics, and fluorescence imaging.

Beate Rau, MD, PhD, highlights advances across gastrointestinal and rectal cancers, as well as the role of intraperitoneal chemotherapy in gastric cancer. Marco Fiore, MD, discusses the evolving surgical approach to retroperitoneal sarcoma, while Piotr Rutkowski, MD, explores progress in melanoma management, from gene expression profiling to new targeted treatments. Ga...

In this week’s VJOncology podcast, leading experts share the latest updates in ADCs in HER2-positive and metastatic breast cancer in recognition of Breast Cancer Awareness Month.

Charles Geyer, MD, discusses pivotal results from the Phase III DESTINY-Breast05 trial, where trastuzumab deruxtecan (T-DXd) significantly improved invasive disease-free and disease-free survival versus trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer, reducing the risk of brain metastases. Sara Tolaney, MD, MPH, highlights the practice-changing reduction in recurrence risk with T-DXd and comments on the expanding role of antibody–drug conjugates (ADCs) in earlier lines of therapy acros...

In this week’s VJOncology podcast, leading experts share key updates presented at the ESMO 2025 Congress in Berlin, Germany.

Sara Tolaney, MD, MPH, highlights the expanding role of ADCs in earlier lines of metastatic breast cancer, presenting data from the DESTINY-Breast09 and ASCENT-03 trials, and discusses results from DESTINY-Breast05, where trastuzumab deruxtecan demonstrated superior outcomes to trastuzumab emtansine in high-risk HER2-positive early breast cancer. Scott Tagawa, MD, reports findings from the PSMAddition trial of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer, showing improved radiographic progression-free survival. Antonio Passaro, MD, PhD, outlines data from the OptiTROP-Lung04 study of...

In this week’s VJOncology podcast, leading experts share the latest updates in the management of hepatocellular carcinoma (HCC) in recognition of Liver Cancer Awareness Month.

Stephen Lam Chan, MD, FRCP, discusses emerging immunotherapy and targeted approaches, including novel TIM3 and TIGIT inhibitors, and findings from the SIERRA study of durvalumab and tremelimumab in advanced HCC. Lorenza Rimassa, MD, reviews the CheckMate 9DW trial establishing nivolumab plus ipilimumab as a new standard of care, while Qi Cheng, PhD, highlights promising results from a Phase II study of irpagratinib plus atezolizumab in FGF19-positive HCC. Ciro Celsa, MD, Ph...

In this week’s VJOncology podcast, we are joined by brain tumor experts Stephen Bagley, MD, MSCE, University of Pennsylvania, Philadelphia, PA, and Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, as they discuss the latest updates in cerebrospinal fluid (CSF) liquid biopsies in brain tumors. They will comment on the rationale and challenges in CSF liquid biopsies in this space, current research in their clinical utility and what the future holds for this area.

In this week’s exclusive VJOncology podcast, we are joined by Javier Martín-Broto, MD, PhD, Fundación Jiménez Díaz University Hospital, Madrid, Spain, who shares expert insights on the evolving role of immunotherapy in sarcoma. He discusses the unique immunosensitivity of alveolar soft part sarcoma, the potential of combining checkpoint inhibitors with anti-angiogenic or anti-CTLA-4 agents, and encouraging results with TCR-T cell therapy in synovial sarcoma and myxoid liposarcoma. The role of biomarkers such as tertiary lymphoid structures (TLS) is also highlighted as a predictor of response to immunotherapy.

In this week’s VJOncology podcast, we have the pleasure to bring you key updates in lung cancer at IASLC 2025 World Conference on Lung Cancer (WCLC), which we attended live in Barcelona, Spain. Join experts John Varlotto, MD, Marshall University, Huntington, WV, Alessio Cortellini, MD, Bio-Medico University, Rome, Italy, Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, Nicolas Girard, MD, Institut Curie, Paris, France, and Kenneth O'Byrne, MD, MB, BCh, Princess Alexandra Hospital, Brisbane, Australia, as they discuss pivotal trials in non-small cell lung cancer (NSCLC) such as the FLAURA2, and ACROSS 2 trials, developments in mesothelioma, and practice-changing data in...

In this week’s podcast from VJOncology, three leading experts provide insights into the latest advances in precision medicine for head and neck cancer.

Luigi Lorini of Humanitas Research Hospital discusses the evolving treatment landscape of immunotherapy in head and neck squamous cell carcinoma. Danny Rischin of the Peter MacCallum Cancer Centre presents findings from a Phase II trial evaluating fianlimab plus cemiplimab in patients with recurrent or metastatic PD-L1–expressing head and neck squamous cell carcinoma. Finally, Jun Ma from Sun Yat-sen University Cancer Center explores the future of immunotherapy in nasopharyngeal carcinoma beyond PD-1 and shar...

In this week’s VJOncology podcast, we will be joined by Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, as he outlines current and emerging strategies for managing HER2-positive metastatic breast cancer after antibody–drug conjugate (ADC) therapy, with a focus on trastuzumab deruxtecan (T-DXd). He discusses the use of tucatinib-based regimens, mechanisms of resistance to agents such as trastuzumab emtansine (T-DM1), and approaches to treating brain metastases, drawing on evidence from trials. The importance of individualized treatment is highlighted, particularly in hormone receptor–positive disease, where CDK4/6 inhibitors may provide added benefit.

In this week’s installment of the VJOncology podcast, we will examine the cutting-edge applications of artificial intelligence in clinical oncology. This episode presents a curated series of expert insights into AI-driven tools for early detection, diagnostic precision, biomarker development, treatment guidance, and prognostic assessment. Leading clinicians and researchers discuss breast, sarcoma, kidney, gastric, and lung cancers, highlighting how AI is being integrated into clinical workflows, risk stratification, and patient-specific decision-making. This episode provides actionable knowledge on leveraging AI to improve diagnostic accuracy, optimize therapeutic strategies, and enhance patient outcomes across multiple tumor types.

Join leading GI cancer experts J. Randolph Hecht, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, Jasmine Mitchell, UCLA Santa Monica Medical Center, Santa Monica, CA, and Jingran Ji, UCLA Santa Monica Medical Center, Santa Monica, CA, as they share key insights from the most impactful gastrointestinal cancer updates presented at ASCO 2025.

In this episode, they discuss pivotal trials including CHALLENGE (NCT00819208), demonstrating that structured exercise can improve disease-free survival in resected colon cancer; ATOMIC (NCT02912559), highlighting the role of adjuvant immunotherapy with atezolizumab in MSI-high colon cancer; and MATTERHORN (NCT04592913), where adding durvalumab to perioperative FLOT...

In this week's VJOncology podcast, we will be covering highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 in Chicago, IL. Gain expert insight on exploratory biomarkers, treatment landscape shifts, and practice-changing trials from leading researchers in the field of genitourinary cancers.

Join renowned speakers Angela Jia, Tian Zhang, Michael Harrison, Margaret Gatti-Mays, and Stefanie Zschaebitz, as they discuss Phase I/II trial results on neoadjuvant combination therapy for cisplatin-ineligible bladder cancer, and strides in personalized vaccines in metastatic prostate cancer.

In this episode of the VJOncology podcast, we explore the evolving landscape of gynecologic cancer care with expert insights recorded at the 2025 ESMO Gynaecological Cancers Congress in Vienna. Ilana Cass, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, discusses new data from the RUBY trial and the impact of dostarlimab in endometrial cancer. Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, presents findings from the TRUST trial, highlighting the value of primary debulking surgery in advanced ovarian cancer. We also hear from Felix Hilpert, MD, Krankenhaus Jerusalem, Hamburg, Germany on overcoming treatment hesitancy in elderly ovarian cancer patients, and Angeles...

In this weeks podcast from VJOncology, five leading experts share updates and insights on the evolving landscape of precision medicine in sarcoma.

Robin Jones discusses the complexities of implementing precision medicine and presents results from a Phase III trial of catequentinib in advanced leiomyosarcoma. Javier Martín-Broto explores recent advances in immunotherapy and shares findings from Cohort 7A of the ImmunoSarc2 trial, evaluating epirubicin and ifosfamide plus nivolumab in undifferentiated pleomorphic sarcoma. Nadia Hindi highlights Cohort 2, which assessed sunitinib and nivolumab in extraskeletal myxoid chondrosarcoma. Ramya Ramaswami addresses unmet needs in Kaposi sarcoma and presents data from a...

In this weeks podcast from VJOncology, five leading experts share updates and insights on the evolving landscape of precision medicine in sarcoma.

Robin Jones discusses the complexities of implementing precision medicine and presents results from a Phase III trial of catequentinib in advanced leiomyosarcoma. Javier Martín-Broto explores recent advances in immunotherapy and shares findings from Cohort 7A of the ImmunoSarc2 trial, evaluating epirubicin and ifosfamide plus nivolumab in undifferentiated pleomorphic sarcoma. Nadia Hindi highlights Cohort 2, which assessed sunitinib and nivolumab in extraskeletal myxoid chondrosarcoma. Ramya Ramaswami addresses unmet needs in Kaposi sarcoma and presents data from a...

In this week’s VJOncology podcast, we have the pleasure to bring you key updates in CAR-T and cellular therapies in brain tumors. Gain expert insights on landmark trials, treatment advances, and shifting screening practices from some of the foremost voices in the field. Topics of discussion include a Phase I trial of intracranial B7H3-directed CAR-T cell therapy in patients with recurrent glioblastoma, effective strategies in anti-glioblastoma CAR-T cells, and dendritic cell therapy in recurrent glioblastoma.

The post CAR-T and cellular therapy updates in brain tumors appeared first on VJOncology.

In this weeks VJOncology podcast, we have the pleasure to bring you key updates in CAR-T and cellular therapies in brain tumors. Gain expert insights on landmark trials, treatment advances, and shifting screening practices from some of the foremost voices in the field. Topics of discussion include a Phase I trial of intracranial B7H3-directed CAR-T cell therapy in patients with recurrent glioblastoma, effective strategies in anti- glioblastoma CAR-T cells, and dendritic cell therapy in recurrent glioblastoma.

This week’s VJOncology podcast episode highlights four breakthrough studies from ESMO GI 2025 in Barcelona, Spain, featuring expert insights on gastrointestinal cancer advances. Coverage includes the EXPEL PANC study combining BXCL701 with pembrolizumab for pancreatic cancer, SIERRA study safety data on the STRIDE regimen for hepatocellular carcinoma, TALENTACE trial results combining TACE with atezolizumab plus bevacizumab, and updated MATTERHORN study data on perioperative immunotherapy for gastric cancer. Leading oncologists share perspectives on these game-changing developments reshaping GI cancer treatment live from Barcelona, Spain.

The post Breakthrough advances from ESMO GI 2025 appeared first on VJOncology.

This week’s VJOncology podcast episode highlights four breakthrough studies from ESMO GI 2025 in Barcelona, Spain, featuring expert insights on gastrointestinal cancer advances. Coverage includes the EXPEL PANC study combining BXCL701 with pembrolizumab for pancreatic cancer, SIERRA study safety data on the STRIDE regimen for hepatocellular carcinoma, TALENTACE trial results combining TACE with atezolizumab plus bevacizumab, and updated MATTERHORN study data on perioperative immunotherapy for gastric cancer. Leading oncologists share perspectives on these game-changing developments reshaping GI cancer treatment live from Barcelona, Spain.

Join esteemed experts Joao Victor Alessi, Hospital Sírio-Libanês, Sao Paolo, Brazil, and Alessandro Di Federico, Dana-Farber Cancer Institute, Boston, MA, as they discuss the most anticipated updates in lung cancer presented at ASCO 2025, as they comment on ground-breaking trials and provide their insights on the significance of the findings and updates.

In this episode, they comment on the potential of new agents like tarlatamab, and pivotal trials such as the OptiTROP-Lung03 trial of sacituzumab tirumotecan in EGFR-mutated non-small cell lung cancer (NSCLC), the CheckMate 816 trial of neoadjuvant nivolumab plus chemotherapy, and the ALNEO trial of al...

Join esteemed experts Joao Victor Alessi, Hospital Sírio-Libanês, Sao Paolo, Brazil, and Alessandro Di Federico, Dana-Farber Cancer Institute, Boston, MA, as they discuss the most anticipated updates in lung cancer presented at ASCO 2025, as they comment on ground-breaking trials and provide their insights on the significance of the findings and updates.

In this episode, they comment on the potential of new agents like tarlatamab, and pivotal trials such as the OptiTROP-Lung03 trial of sacituzumab tirumotecan in EGFR-mutated non-small cell lung cancer (NSCLC), the CheckMate 816 trial of neoadjuvant nivolumab plus chemotherapy, and the ALNEO trial of al...

Join our experts as they delve into the latest advancements in breast cancer presented at ASCO 2025, as they comment on highly anticipated trials and gives their perspectives on the significance of the findings and updates.

In this episode, Kevin Kalinsky, Emory University Hospital, Atlanta, GA, and Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY, receive updates on trials presented at this year’s ASCO, including the ASCENT-04 trial (NCT05382286) of sacituzumab govitecan and pembrolizumab in PD-L1-positive triple-negative breast cancer (TNBC) and the DESTINY-Breast09 trial (NCT04784715) of first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in patients with HER2+ br...

Join our experts as they delve into the latest advancements in breast cancer presented at ASCO 2025, as they comment on highly anticipated trials and gives their perspectives on the significance of the findings and updates.

In this episode, Kevin Kalinsky, Emory University Hospital, Atlanta, GA, and Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY, receive updates on trials presented at this year’s ASCO, including the ASCENT-04 trial (NCT05382286) of sacituzumab govitecan and pembrolizumab in PD-L1-positive triple-negative breast cancer (TNBC) and the DESTINY-Breast09 trial (NCT04784715) of first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in patients with HER2+ br...

In this weeks VJOncology podcast, we have the pleasure to bring you key updates in gynecological cancer from ASCO 2025, which we attended live in Chicago, IL. Join leading experts as they comment on key trials and provide their insights on the ever-evolving treatment landscape and screening patterns.

Dr Jyoti Mayadev gives an overview of highly anticipated trials at the conference including the CALLA, OUTBACK and KEYNOTE-A18 trials, and Dr Shannon Westin discusses findings from the ctDNA findings from the DUO-E trial in endometrial cancer. Dr Kamran Ahmed comments on the efficacy of SBRT followed by atezolizumab in...

In this weeks VJOncology podcast, we have the pleasure to bring you key updates in gynecological cancer from ASCO 2025, which we attended live in Chicago, IL. Join leading experts as they comment on key trials and provide their insights on the ever-evolving treatment landscape and screening patterns.

Dr Jyoti Mayadev gives an overview of highly anticipated trials at the conference including the CALLA, OUTBACK and KEYNOTE-A18 trials, and Dr Shannon Westin discusses findings from the ctDNA findings from the DUO-E trial in endometrial cancer. Dr Kamran Ahmed comments on the efficacy of SBRT followed by a...

In this ASCO 2025 edition of VJOncology podcasts, we spotlight five game-changing studies set to reshape cancer care across multiple tumor types.

Join our host and a panel of leading oncology experts as they unpack the most impactful data from this year’s American Society of Clinical Oncology Annual Meeting. Discover pivotal insights from the MATTERHORN trial in gastric cancer, explore KRAS G12C-targeted combinations in NSCLC, and delve into resistance-prevention strategies in HR+/HER2– breast cancer with findings from the SERENA-6 trial. We also explore the potential of mRNA-based bispecific antibodies for solid tumors and analyze expanded resu...

In this ASCO 2025 edition of VJOncology podcasts, we spotlight five game-changing studies set to reshape cancer care across multiple tumor types.

Join our host and a panel of leading oncology experts as they unpack the most impactful data from this year’s American Society of Clinical Oncology Annual Meeting. Discover pivotal insights from the MATTERHORN trial in gastric cancer, explore KRAS G12C-targeted combinations in NSCLC, and delve into resistance-prevention strategies in HR+/HER2– breast cancer with findings from the SERENA-6 trial. We also explore the potential of mRNA-based bispecific antibodies for solid tumors and analyze expanded resu...

Welcome to another episode of the VJ Oncology Podcast, where we bring you the forefront of cancer research and clinical practice. This week, we focus on the revolutionary field of cell therapy for solid tumors, with particular emphasis on lung cancer and melanoma, as discussed during the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, held in Miami, FL.

Join Dr. Alison Betoff-Warner and Dr. Ben Creelan as they discuss the potential of targets like TILs, TCRs, and CAR-Ts. Learn about the challenges posed by IL-2 toxicity and discover the latest developments in emerging trials, including promising...

Welcome to another episode of the VJ Oncology Podcast, where we bring you the forefront of cancer research and clinical practice. This week, we focus on the revolutionary field of cell therapy for solid tumors, with particular emphasis on lung cancer and melanoma.

Join Dr. Alison Betoff-Warner and Dr. Ben Creelan as they discuss the potential of targets like TILs, TCRs, and CAR-Ts. Learn about the challenges posed by IL-2 toxicity and discover the latest developments in emerging trials, including promising advancements in therapies targeting PREM and P53.

Don't miss out on these expert insights...

In this week’s podcast, we take you through the latest episodes of the VJOncoAlert Journal Club—a collaborative series from VJOncology and OncoAlert that brings together leading oncology experts to discuss the most impactful and practice-changing research in the field.

We are joined by Misty Shields, MD, PhD, from the Indiana University Simon Comprehensive Cancer Center in Indianapolis, IN, who discusses the latest updates in small cell lung cancer. Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute in London, UK, and Brian Rini, MD, FASCO, of Vanderbilt-Ingram Cancer Center in Nashville, TN, comment on the heal...

In this week’s podcast, we take you through the latest episodes of the VJOncoAlert Journal Club—a collaborative series from VJOncology and OncoAlert that brings together leading oncology experts to discuss the most impactful and practice-changing research in the field.

We are joined by Misty Shields, MD, PhD, from the Indiana University Simon Comprehensive Cancer Center in Indianapolis, IN, who discusses the latest updates in small cell lung cancer. Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute in London, UK, and Brian Rini, MD, FASCO, of Vanderbilt-Ingram Cancer Center in Nashville, TN, comment on the heal...

Welcome to this week’s podcast by VJOncology, where we delve into the latest developments in adjuvant therapy for hepatocellular carcinoma. Join five leading experts as they discuss cutting-edge research and its impact on clinical practices.

Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS Medical School Singapore, Singapore, and Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Canc...

Welcome to this week's podcast by VJOncology, where we delve into the latest developments in adjuvant therapy for hepatocellular carcinoma. Join five leading experts as they discuss cutting-edge research and its impact on clinical practices.

Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS Medical School Singapore, Singapore, and Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Ce...

In this week’s VJOncology podcast, we are focusing again on Prostate Cancer Awareness Month, where we have collaborated with experts on liquid biopsies for tracking and predicting treatment outcomes in metastatic castration-resistant prostate cancer.

Join Chinmay Jani from the Sylvester Comprehensive Cancer Centre, Xin Gao from Massachusetts General Hospital Cancer Center, Christos Kyriakopoulos from the University of Wisconsin, Andrew Armstrong from the Duke Cancer Institute, and Susan Halabi from Duke University Medical Center, as they present various trial updates and their exclusive insights from this burgeoning field.

The post Prostate cancer awareness month: advances in...

In this week's VJOncology podcast, we are focusing again on Prostate Cancer Awareness Month, where we have collaborated with experts on liquid biopsies for tracking and predicting treatment outcomes in metastatic castration-resistant prostate cancer.

Join Chinmay Jani from the Sylvester Comprehensive Cancer Centre, Xin Gao from Massachusetts General Hospital Cancer Center, Christos Kyriakopoulos from the University of Wisconsin, Andrew Armstrong from the Duke Cancer Institute, and Susan Halabi from Duke University Medical Center, as they present various trial updates and their exclusive insights from this burgeoning field. 

In this weeks VJOncology podcast, we explore key update from BTOG 2025 in thoracic oncology.

Prof. Sanjay Popat discusses the evolving role of ADCs in lung cancer treatment, focusing on efficacy, toxicity management, and biomarker integration. Prof. Samreen Ahmed examines ADC resistance mechanisms, drawing insights from breast cancer therapy to refine drug development strategies. Prof. Robert Rintoul reviews a new UK Lung Cancer Coalition report on genomic testing challenges and strategic solutions for faster diagnostics. Dr Adam Januszewski highlights the complexities of implementing genomics in the UK and the need for a streamlined approach. Prof. Neal Nivani concludes...

In this weeks VJOncology podcast, we explore key update from BTOG 2025 in thoracic oncology.

Prof. Sanjay Popat discusses the evolving role of ADCs in lung cancer treatment, focusing on efficacy, toxicity management, and biomarker integration. Prof. Samreen Ahmed examines ADC resistance mechanisms, drawing insights from breast cancer therapy to refine drug development strategies. Prof. Robert Rintoul reviews a new UK Lung Cancer Coalition report on genomic testing challenges and strategic solutions for faster diagnostics. Dr Adam Januszewski highlights the complexities of implementing genomics in the UK and the need for a streamlined approach. Prof. Neal Nivani concludes...

In this weeks VJOncology podcast, three oncology experts delve into the transformative potential of liquid biopsy in breast cancer treatment.

First, Michail Ignatiadis (Jules Bordet Institute, Brussels, Belgium) discusses the clinical applications and challenges of utilizing liquid biopsy in metastatic breast cancer, focusing on the Phase III TREAT ctDNA trial (NCT05512364) and its implications for ER-positive, HER2-negative cases. Next, Marina Sharifi (University of Wisconsin Carbone Cancer Center, Madison, WI) introduces an innovative fragmentomic analysis of circulating tumor DNA (ct-DNA) to discern ER status in metastatic breast cancer, potentially minimizing the need for invasive tissue biopsies. Finally...

In this weeks VJOncology podcast, three oncology experts delve into the transformative potential of liquid biopsy in breast cancer treatment.

First, Michail Ignatiadis (Jules Bordet Institute, Brussels, Belgium) discusses the clinical applications and challenges of utilizing liquid biopsy in metastatic breast cancer, focusing on the Phase III TREAT ctDNA trial (NCT05512364) and its implications for ER-positive, HER2-negative cases. Next, Marina Sharifi (University of Wisconsin Carbone Cancer Center, Madison, WI) introduces an innovative fragmentomic analysis of circulating tumor DNA (CT-DNA) to discern estrogen receptor status in metastatic breast cancer, potentially minimizing the need for invasive tissue biopsies...

In this podcast, we will discuss recent developments in radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment, as part one of our series for Prostate Cancer Awareness Month. Listen to leading experts as they share breakthroughs in mCRPC research.

First, Omid Yazdanpanah, MD, from the University of California, shares findings from the VISION trial, which assessed 177Lu-PSMA-617 with or without androgen receptor pathway inhibitors (ARPIs) in patients with mCRPC, as well as the potential of radioligands with ARPIs in in the ENZA-p trial. Andrei Gafita, MD, from Johns Hopkins Medicine, subsequently discusses the significance of post-therapy...

In this podcast, we will discuss recent developments in radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment, as part one of our series for Prostate Cancer Awareness Month. Listen to leading experts as they share breakthroughs in mCRPC research.

First, Omid Yazdanpanah, MD, from the University of California, shares findings from the VISION trial, which assessed 177Lu-PSMA-617 with or without androgen receptor pathway inhibitors (ARPIs) in patients with mCRPC, as well as the potential of radioligands with ARPIs in in the ENZA-p trial. Andrei Gafita, MD, from Johns Hopkins Medicine, subsequently discusses the significance o...

Join us in this episode as we go through the latest advancements in genitourinary cancer treatment presented at ASCO GU 2025 in San Francisco. Our expert guests provide insights into ground-breaking trials and studies that are reshaping the landscape of cancer therapy.

Join Nadine Houede, Xinan Sheng, Nicholas James, and Wenxin Xu, as they discuss highly anticipated updates such as results of neoadjuvant durvalumab with chemotherapy in high-risk high-risk upper tract urothelial carcinoma (UTUC), disitamab vedotin and toripalimab in HER2-expressing bladder cancer, and updates from the STAMPEDE trial.

The post Key updates at ASCO GU 2025...

Join us in this episode as we go through the latest advancements in genitourinary cancer treatment presented at ASCO GU 2025 in San Francisco. Our expert guests provide insights into ground-breaking trials and studies that are reshaping the landscape of cancer therapy.

Join Nadine Houede, Xinan Sheng, Nicholas James, and Wenxin Xu, as they discuss highly anticipated updates such as results of neoadjuvant durvalumab with chemotherapy in high-risk high-risk upper tract urothelial carcinoma (UTUC), disitamab vedotin and toripalimab in HER2-expressing bladder cancer, and updates from the STAMPEDE trial. 

Welcome to this week’s podcast by VJOncology, where we delve into the emerging trends and challenges in the field of cellular therapies for oncology. Our expert panel includes Leonardo Ferreira (The Medical University of South Carolina, Charleston, SC), who discusses the groundbreaking potential and current obstacles of CAR T cells in treating solid tumors, emphasizing the innovative role of chimeric antigen receptor regulatory T cells.

We also hear from Sebastian Klobuch (Netherlands Cancer Institute, Amsterdam, The Netherlands) on the advancements in TIL and TCR-modified therapies. He explores potential ways to mitigate treatment toxicities and expand the ap...

Welcome to this week's podcast by VJOncology, where we delve into the emerging trends and challenges in the field of cellular therapies for oncology. Our expert panel includes Leonardo Ferreira (The Medical University of South Carolina, Charleston, SC), who discusses the groundbreaking potential and current obstacles of CAR T cells in treating solid tumors, emphasizing the innovative role of chimeric antigen receptor regulatory T cells.

We also hear from Sebastian Klobuch (Netherlands Cancer Institute, Amsterdam, The Netherlands) on the advancements in TIL and TCR-modified therapies. He explores potential ways to mitigate treatment toxicities and expand the applicability...

In this podcast, we explore the latest advancements in the treatment of PD-1 refractory melanoma. This week, we are joined by Allison Betof Warner (Stanford Cancer Center, Stanford, CA) and Omid Hamid (The Angeles Clinic and Research Institute, Los Angeles, CA) and Inderjit Mehmi (The Angeles Clinic and Research Institute, Los Angeles, CA).

We will hear about the clinical definitions and significance of PD-1 resistance, including insights from SITC on primary and secondary resistance. The discussion will also highlight the implications for clinical trial design and strategies to overcome resistance in melanoma therapy. Updates on emerging treatment opt...

In this podcast, we explore the latest advancements in the treatment of PD-1 refractory melanoma. This week, we are joined by Allison Betof Warner (Stanford Cancer Center, Stanford, CA) and Omid Hamid (The Angeles Clinic and Research Institute, Los Angeles, CA) and Inderjit Mehmi (The Angeles Clinic and Research Institute, Los Angeles, CA).

We will hear about the clinical definitions and significance of PD-1 resistance, including insights from SITC on primary and secondary resistance. The discussion will also highlight the implications for clinical trial design and strategies to overcome resistance in melanoma therapy. Updates on emerging treatment opt...

In this week’s podcast, we will provide updates the emerging roles of circulating tumor DNA (ctDNA) in managing colorectal cancer. We are joined by Michael Brian LaPelusa, MD, University of Texas MD Anderson Cancer Center, Houston, TX; Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina; Anup Kasi, MD, MPH, University of Kansas Cancer Center, Kansas City, KS; Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; and Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX.

The role of ctDNA in predi...

In this week’s podcast, we will provide updates the emerging roles of circulating tumor DNA (ctDNA) in managing colorectal cancer. We are joined by Michael Brian LaPelusa, MD, University of Texas MD Anderson Cancer Center, Houston, TX; Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina; Anup Kasi, MD, MPH, University of Kansas Cancer Center, Kansas City, KS; Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; and Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX.

The role of ctDNA in predi...

In this week’s podcast, we will discuss the most recent developments in breast cancer from the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. Join us as renowned experts exclusively speak with us on anticipated findings from clinical trials across different breast cancer subtypes.

Gaia Griguolo from University of Padova in Italy, first discusses the PATINA trial, which investigated the addition of palbociclib to anti-HER2 and endocrine therapy in HR+/HER2+ breast cancer and Puneet Singh from The University of Texas MD Anderson Cancer Center comments on the COMET trial, which compared active mo...

This week’s podcast from VJOncology brings you the latest updates on novel checkpoint inhibitors that target LAG-3, TIGIT, and TIM3 in solid tumors. Our panel of experts share the latest findings from their clinical trials that tested the efficacy of different immune checkpoint inhibitors in neoplastic tumors.

Myriam Chalabi from the Netherlands Cancer Institute shares results from the NICHE-2 and NICHE-3 trials on MMR-deficient colon cancer, and Girish Kulkarni from the University of Toronto discusses the cohort C section of the KEYNOTE-057 trial, followed by the potential role of TIGIT/LAG-3 inhibition for urothelial carcinoma treatment. Gh...

In this week’s podcast, we will discuss the most recent developments in breast cancer from the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. Join us as renowned experts exclusively speak with us on highly anticipated findings from clinical trials across different breast cancer subtypes.

Gaia Griguolo from University of Padova in Italy, first discusses the PATINA trial, which investigated the addition of palbociclib to anti-HER2 and endocrine therapy in HR+/HER2+ breast cancer and Puneet Singh from The University of Texas MD Anderson Cancer Center comments on the COMET trial, which compared ac...

This week’s podcast from VJOncology brings you the latest updates on novel checkpoint inhibitors that target LAG-3, TIGIT, and TIM3 in solid tumors. Our panel of experts share the latest findings from their clinical trials that tested the efficacy of different immune checkpoint inhibitors in neoplastic tumors.

Myriam Chalabi from the Netherlands Cancer Institute shares results from the NICHE-2 and NICHE-3 trials on MMR-deficient colon cancer, and Girish Kulkarni from the University of Toronto discusses the cohort C section of the KEYNOTE-057 trial, followed by the potential role of TIGIT/LAG-3 inhibition for urothelial carcinoma treatment. Gh...

This week’s podcast from VJOncology brings you key updates in antibody drug conjugates (ADCs) for gastrointestinal cancer. Our expert panel discusses the potential of ADCs targeting HER2, CMET, and CEACAM5 in gastric and colorectal cancers.

Hear from experts Kohei Shitara (National Cancer Center Hospital East), Yelena Janjigian (Memorial Sloan Kettering Cancer Center), John Strickler (Duke Cancer Institute), and Scott Kopetz (MD Anderson Cancer Center) as they provide an overview of the latest in ADCs for gastrointestinal cancers. Highlights include novel treatment strategies in HER2-expressing gastric cancer, findings from the DESTINY-Gastric03 and ABBV-400 trials, and the ro...

This week’s podcast from VJOncology brings you key updates in antibody drug conjugates (ADCs) for gastrointestinal cancer. Our expert panel discusses the potential of ADCs targeting HER2, CMET, and CEACAM5 in gastric and colorectal cancers.

Hear from experts Kohei Shitara (National Cancer Center Hospital East), Yelena Janjigian (Memorial Sloan Kettering Cancer Center), John Strickler (Duke Cancer Institute), and Scott Kopetz (MD Anderson Cancer Center) as they provide an overview of the latest in ADCs for gastrointestinal cancers. Highlights include novel treatment strategies in HER2-expressing gastric cancer, findings from the DESTINY-Gastric03 and ABBV-400 trials, and the ro...

This week’s podcast from VJOncology explores key advancements in the treatment of PD-1 refractory melanoma. Hear from leading experts, Alison Betoff Warner (Stanford University, Stanford, CA), Andrew Furness (Royal Marsden Hospital, London, UK), Anna Di Giacomo (University Hospital of Siena, Siena, Italy), María Vieito (Vall d’Hebron Institute of Oncology, Barcelona, Spain), and Yana Najjar (UPMC Hillman Cancer Center, Pittsburgh, PA), as they share insights into cutting-edge therapies and trials.

Highlights include the FDA approval of TIL therapy in metastatic melanoma, early findings on off-the-shelf T-cell therapy, and results from the NIBIT-ML1 trial (NCT04250246) investigating a tri...

This week’s podcast from VJOncology explores key advancements in the treatment of PD-1 refractory melanoma. Hear from leading experts, Alison Betoff Warner (Stanford University, Stanford, CA), Andrew Furness (Royal Marsden Hospital, London, UK), Anna Di Giacomo (University Hospital of Siena, Siena, Italy), María Vieito (Vall d’Hebron Institute of Oncology, Barcelona, Spain), and Yana Najjar (UPMC Hillman Cancer Center, Pittsburgh, PA), as they share insights into cutting-edge therapies and trials.

Highlights include the FDA approval of TIL therapy in metastatic melanoma, early findings on off-the-shelf T-cell therapy, and results from the NIBIT-ML1 trial (NCT04250246) investigating a tri...

In this week’s podcast, we explore the critical links between environmental factors and lung cancer risk, focusing on the impacts of climate change, pollution, and exposure in conflict zones. Join us as we hear from experts Felipe Roitberg, MD, Brazilian Hospital Services Company (EBSERH), Brasília, Brazil, and Leticia Nogueira, MD, American Cancer Society, Palm Harbor, FL.

They share their insights from the IASLC 2024 World Conference on Lung Cancer (WCLC), highlighting the challenges and innovative solutions emerging from resource-scarce communities worldwide. Discover how climate change affects every stage of cancer care, from prevention to treatment, and the i...

In this week’s podcast, we explore the critical links between environmental factors and lung cancer risk, focusing on the impacts of climate change, pollution, and exposure in conflict zones. Join us as we hear from experts Felipe Roitberg, MD, Brazilian Hospital Services Company (EBSERH), Brasília, Brazil, and Leticia Nogueira, MD, American Cancer Society, Palm Harbor, FL.

They share their insights from the IASLC 2024 World Conference on Lung Cancer, highlighting the challenges and innovative solutions emerging from resource-scarce communities worldwide. Discover how climate change affects every stage of cancer care, from prevention to treatment, and the imp...

This week’s podcast from VJOncology brings you key updates in gastrointestinal cancer from the European Society of Medical Oncology (ESMO) 2024 annual meeting, which took place in Barcelona, Spain.

Hear from experts, Jessie Elliot (Trinity St. James’s Cancer Institute), Myriam Chalabi (Netherlands Cancer Institute), and Changhoon Yoo (Asan Medical Center) as they discuss the latest in biliary tract and colon cancers, as well as gastric and gastroesophageal junction adenocarcinoma. Highlights include findings from the TOPGEAR trial, extended follow-up results from the NICHE-2 and the NICHE-3 trials, as well as findings from the NIFTY and NALIRICC studies. 

This week’s podcast from VJOncology brings you key updates in gastrointestinal cancer from the European Society of Medical Oncology (ESMO) 2024 annual meeting, which took place in Barcelona, Spain.

Hear from experts, Jessie Elliot (Trinity St. James’s Cancer Institute), Myriam Chalabi (Netherlands Cancer Institute), and Changhoon Yoo (Asan Medical Center) as they discuss the latest in biliary tract and colon cancers, as well as gastric and gastroesophageal junction adenocarcinoma. Highlights include findings from the TOPGEAR trial, extended follow-up results from the NICHE-2 and the NICHE-3 trials, as well as findings from the NIFTY and NALIRICC studies. 

In this week’s podcast, we bring you the latest developments in the field of refractory colorectal cancer. We are joined by Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain; Kathrin Heinrich, MD, Ludwig-Maximilians-Universität München, Munich, Germany; Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy; and Cristina Smolenski, MD, Gustave Roussy, Villejuif, France.

We’ll hear about the current treatment landscape for refractory metastatic colorectal cancer, especially in the third-line settings, updates from the SOREGATT trial, which assessed regorafenib with chemotherapy in pretreated colorectal cancer, and the emerging role of fruquintinib, a selective...

In this week’s podcast, we bring you the latest developments in the field of refractory colorectal cancer. We are joined by Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain; Kathrin Heinrich, MD, Ludwig-Maximilians-Universität München, Munich, Germany; Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy; and Cristina Smolenski, MD, Gustave Roussy, Villejuif, France.

We’ll hear about the current treatment landscape for refractory metastatic colorectal cancer, especially in the third-line settings, updates from the SOREGATT trial, which assessed regorafenib with chemotherapy in pretreated colorectal cancer, and the emerging role of fruquintinib, a selective...

In this podcast, we bring you exclusive insights from the 43rd Congress of the European Society of Surgical Oncology (ESSO 43), held in Antwerp, Belgium. We will be joined by Isabel Rubio, MD, PhD (Vall d’Hebron University Hospital, Barcelona, Spain), who discusses the dual focus of modern cancer surgery and the transformative impact of robotic surgery; Sylvie Bonvalot, MD, PhD, HDR (Institut Curie, Paris, France), recipient of the ESSO Lifetime Achievement Award 2024, who reflects on her extensive experience with desmoid tumors and sarcoma surgery; and Mitsuru Sasako, MD, PhD (Yodogawa Christian Hospital, Osaka, Japan), recipient of the ESSO Gold Me...

In this podcast, we bring you exclusive insights from the 43rd Congress of the European Society of Surgical Oncology (ESSO 43), held in Antwerp, Belgium. We will be joined by Isabel Rubio, MD, PhD (Vall d'Hebron University Hospital, Barcelona, Spain), who discusses the dual focus of modern cancer surgery and the transformative impact of robotic surgery; Sylvie Bonvalot, MD, PhD, HDR (Institut Curie, Paris, France), recipient of the ESSO Lifetime Achievement Award 2024, who reflects on her extensive experience with desmoid tumors and sarcoma surgery; and Mitsuru Sasako, MD, PhD (Yodogawa Christian Hospital, Osaka, Japan), recipient of the ESSO Gold Medal 2024...

In this week’s podcast, we bring you updates from the ESMO 2024 Congress in Barcelona, Spain, featuring expert discussions on cutting-edge oncology research. We are joined by Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK; Minke Lukas, MD, Netherlands Cancer Institute, Amsterdam, Netherlands; Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL; Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden Hospital, London, UK; Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Italy; and Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Germany.

We’ll hear about final overall survival results from the Phase III KEYNOTE...

In this week’s podcast, we bring you updates from the ESMO 2024 Congress in Barcelona, featuring expert discussions on cutting-edge oncology research. We are joined by Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK; Minke Lukas, MD, Netherlands Cancer Institute, Amsterdam; Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL; Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden Hospital, London; Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Italy; and Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Germany.

We’ll hear about final overall survival results from the Phase II KEYNOTE-522 trial (NCT03036488) of pembr...

In this podcast, we bring you the latest insights into managing brain metastases, with expert commentary from Minesh Mehta, MD, Miami Cancer Institute, Miami, FL; Sunandana Chandra, MD, MS, Northwestern University, Chicago, IL; Gaia Griguolo, MD, University of Padova, Padova, Italy; Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel; and Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China,.

We will cover key findings from the Phase III METIS trial (NCT02831959), which explored Tumor Treating Fields (TTFields) therapy in patients with non-small cell lung cancer and brain metastases. Other topics include the...

In this podcast, we bring you the latest insights into managing brain metastases, with expert commentary from Manesh Mehta, MD, Miami Cancer Institute, Miami, FL; Sunandana Chandra, MD, MS, Northwestern University, Chicago, IL; Gaia Griguolo, MD, University of Padova, Padova, Italy; Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel; and Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China,.

We will cover key findings from the Phase III METIS trial (NCT02831959), which explored Tumor Treating Fields (TTFields) therapy in patients with non-small cell lung cancer and brain metastases. Other topics include the...

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat genitourinary cancer. This week we will be joined by Camillo Porta, MD, University of Bari Aldo Moro, Bari, Italy, Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA,  Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Maria Bourlon, MD, MS, El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

We will cover findings from key trials, including CHECKMATE 901 on nivolumab with gemcitabine and cisplatin for metastatic urothelial carci...

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat genitourinary cancer. This week we will be joined by Camillo Porta, MD, University of Bari Aldo Moro, Bari, Italy, Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA,  Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Maria Bourlon, MD, MS, El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

We will discuss key findings from several pivotal trials, including the CHECKMATE 901 trial (NCT03036098), which evaluates nivolumab in combi...

In this week’s podcast, we will be covering recent updates and integrating precision medicine for the treatment of colorectal cancer. We’ll be covering a wide range of topics including biomarker-driven treatments, challenges in using minimal residual disease in the clinic and more.

Listen to expert insights from Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX, Giulia Martini, University of Campania Luigi Vanvitelli, Naples, Italy, Paolo Manca, Memorial Sloan Kettering Cancer Center, New York, NY, and Eric Christensen, John Hopkins Medicine, Baltimore, MD, as they discuss hurdles and opportunities in precision medicine for...

In this week's podcast, we will be covering recent updates and integrating precision medicine for the treatment of colorectal cancer. We'll be covering a wide range of topics including biomarker-driven treatments, challenges in using minimal residual disease in the clinic and more.

Listen to expert insights from Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX, Giulia Martini, University of Campania Luigi Vanvitelli, Naples, Italy, Paolo Manca, Memorial Sloan Kettering Cancer Center, New York, NY, and Eric Christensen, John Hopkins Medicine, Baltimore, MD, as they discuss hurdles and opportunities in precision medicine for colorectal...

In this podcast, we join leading experts Randy Hecht from UCLA, Diane Simeone from University of California San Diego, and Ben Schechter from Dana-Farber Cancer Institute as they delve into groundbreaking advancements in GI cancer therapies, as presented at the latest iwCAR-T workshop in Miami, Florida.

Explore the latest updates and insights on translational research in pancreatic cancer, including innovative biopsy techniques and the evolving role of immuno-oncology in treating solid tumors. Discover the potential of new cell therapies like TAC T-cells and the promising Claudin 18.2-targeted therapies, highlighting their efficacy and safety profiles. These discussions underscore...

In this podcast, we join leading experts Randy Hecht from UCLA, Diane Simeone from University of California San Diego, and Ben Schechter from Dana-Farber Cancer Institute as they delve into groundbreaking advancements in GI cancer therapies, as presented at the latest iwCAR-T workshop in Miami, Florida.

Explore the latest updates and insights on translational research in pancreatic cancer, including innovative biopsy techniques and the evolving role of immuno-oncology in treating solid tumors. Discover the potential of new cell therapies like TAC T-cells and the promising Claudin 18.2-targeted therapies, highlighting their efficacy and safety profiles. These discussions underscore...

In this week’s podcast, we join experts Allison Betof Warner from Stanford Medicine, Amod Sarnaik from Moffitt Cancer Center, and Elizabeth Loggers from Fred Hutchinson Cancer Center on transformative innovations in cell therapies for melanoma and sarcomas, as presented at the most recent iwCAR-T workshop in Miami, Florida.

Discover the latest updates and perspectives on advanced TIL therapies, including their promising progression-free survival results and new protocols for melanoma-induced brain metastases, along with updates on TCR-based therapies for synovial sarcoma. These developments underscore the need for continued research in adjuvant treatment settings and tumor immunology.

...

In this week’s podcast, we join experts Allison Betof Warner from Stanford Medicine, Amod Sarnaik from Moffitt Cancer Center, and Elizabeth Loggers from Fred Hutchinson Cancer Center on transformative innovations in cell therapies for melanoma and sarcomas, as presented at the most recent iwCAR-T workshop in Miami, Florida.

Discover the latest updates and perspectives on advanced TIL therapies, including their promising progression-free survival results and new protocols for melanoma-induced brain metastases, along with updates on TCR-based therapies for synovial sarcoma. These developments underscore the need for continued research in adjuvant treatment settings and tumor immunology.

In this week’s episode, we join Jennifer Specht from Fred Hutchinson Cancer Center, Saurabh Garg from Moffitt Cancer Center, and Rizwan Romee from Dana-Farber Cancer Institute on pioneering advancements in CAR-T cell therapies for breast and gynecological cancers, as discussed at the recent 6th annual iwCAR-T workshop in Miami, Florida.

Tune in to learn about the fascinating evolution of ROR1-targeting CAR-T cells for triple negative breast cancer, NK-cell targeting CAR-T therapeutics in ovarian cancer, and combinatorial therapy using dendritic cells against HER2-positive breast cancer.  As their development progresses, several challenges and advantages come to lig...

In this week's episode, we join Jennifer Specht from Fred Hutchinson Cancer Center, Saurabh Garg from Moffitt Cancer Center, and Rizwan Romee from Dana-Farber Cancer Institute on pioneering advancements in CAR-T cell therapies for breast and gynecological cancers, as discussed at the recent 6th annual iwCAR-T workshop in Miami, Florida.

Tune in to learn about the fascinating evolution of ROR1-targeting CAR-T cells for triple negative breast cancer, NK-cell targeting CAR-T therapeutics in ovarian cancer, and combinatorial therapy using dendritic cells against HER2-positive breast cancer.  As their development progresses, several challenges and advantages come to light. Duration: 00:23:34

Welcome to another episode of VJOncology! In this episode, we dive into cutting-edge CAR-T cell therapies for the management of lung cancers, discussed at the sixth International Workshop on CAR-T in Miami, Florida.

Join Julian Molina from the Mayo Clinic, Ben Creelan from Moffitt Cancer Center, and Adam Schoenfeld from Memorial Sloan Kettering Cancer Center as they explore innovative CAR-T strategies and their applications in thoracic oncology. They address the challenges of integrating cell therapies in clinical practice, the potential for tumor cell banking, and the implications of tumor microenvironment modulation.

Discover insights into the...

Welcome to another episode of VJOncology! In this episode, we dive into cutting-edge CAR-T cell therapies for the management of lung cancers, discussed at the sixth International Workshop on CAR-T in Miami, Florida.

Join Julian Molina from the Mayo Clinic, Ben Creelan from Moffitt Cancer Center, and Adam Schoenfeld from Memorial Sloan Kettering Cancer Center as they explore innovative CAR-T strategies and their applications in thoracic oncology. They address the challenges of integrating cell therapies in clinical practice, the potential for tumor cell banking, and the implications of tumor microenvironment modulation.

Discover insights into the...

In this week’s podcast, we will discuss the most recent developments in colorectal cancer from the 2024 ASCO and ESMO Gastrointestinal (GI) Annual Meetings held in Chicago, IL and Munich, Germany respectively. Join us as five renowned experts discuss highly anticipated findings from clinical trials across different colorectal cancer subtypes.

Heinz-Josef Lenz from the University of Southern California first comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer and Sara Lonardi from the Veneto Institute of Oncology in Padua, Italy, discusses the health-related quality of life outcomes fr...

In this week’s podcast, we will discuss the most recent developments in colorectal cancer from the 2024 ASCO and ESMO Gastrointestinal (GI) Annual Meetings held in Chicago, IL and Munich, Germany respectively. Join us as five renowned experts discuss highly anticipated findings from clinical trials across different colorectal cancer subtypes.

Heinz-Josef Lenz from the University of Southern California first comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer and Sara Lonardi from the Veneto Institute of Oncology in Padua, Italy, discusses the health-related quality of life outcomes fr...

Welcome to another episode of VJ Oncology Podcasts! Today, we spotlight key advances in skin cancer research shared at ASCO 2024. Join us as six leading experts reveal groundbreaking findings from recent clinical trials.

First, Georgina Long from the University of Sydney discusses the NADINA trial, a landmark Phase III study on neoadjuvant immunotherapy for melanoma. Next, Omid Hamid from The Angeles Clinic presents early results from a Phase I trial of IMC-F106C in metastatic cutaneous melanoma. Hear insights from Meredith McKean, Sapna Patel, Joseph J. Sacco, and Rodabe Amaria on innovative therapies and trial results shaping...

Welcome to another episode of VJ Oncology Podcasts! Today, we spotlight key advances in skin cancer research shared at ASCO 2024. Join us as six leading experts reveal groundbreaking findings from recent clinical trials.

First, Georgina Long from the University of Sydney discusses the NADINA trial, a landmark Phase III study on neoadjuvant immunotherapy for melanoma. Next, Omid Hamid from The Angeles Clinic presents early results from a Phase I trial of IMC-F106C in metastatic cutaneous melanoma. Hear insights from Meredith McKean, Sapna Patel, Joseph J. Sacco, and Rodabe Amaria on innovative therapies and trial results shaping...

Welcome to another episode of VJ Oncology! In this episode, we delve into pioneering CAR-T strategies for head and neck cancers and brain tumors, as discussed at the recent iwCAR-T workshop in Miami, Florida.

Join Kedar Khartani from Moffitt Cancer Center and Susanna Baumeister from Dana-Farber Cancer Institute as they explore groundbreaking CAR-T approaches and clinical trials targeting glioblastoma and neuroblastoma. They address the challenges and future prospects of commercializing these therapies, particularly for rare and pediatric cancers.

Discover the exciting developments in ALK-targeting CAR-T cells for neuroblastoma and new antigen-selected TIL therapies for head...

Welcome to another episode of VJ Oncology! In this episode, we delve into pioneering CAR-T strategies for head and neck cancers and brain tumors, as discussed at the recent iwCAR-T workshop in Miami, Florida.

Join Kedar Khartani from Moffitt Cancer Center and Susanna Baumeister from Dana-Farber Cancer Institute as they explore groundbreaking CAR-T approaches and clinical trials targeting glioblastoma and neuroblastoma. They address the challenges and future prospects of commercializing these therapies, particularly for rare and pediatric cancers.

Discover the exciting developments in ALK-targeting CAR-T cells for neuroblastoma and new antigen-selected TIL therapies for head...

This week, we bring you key highlights from European Lung Cancer Congress (ELCC) 2024, which took place in Prague, Czech Republic, including the EVOKE-02, IMscin002, FLAURA2, MARIPOSA-2 and PAPILLON clinical trials. Hear from Federico Cappuzzo, AUSL della Romagna-Ravenna, Ravenna, Italy, Natalia Valdiviezo, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru, Alexander Spira, Next Oncology-Virginia VCS, Joshua Sabari, NYU Langone Health, New York, NY, as they talk on exciting results in lung cancer.

The post ELCC 2024 Highlights appeared first on VJOncology.

This week, we bring you key highlights from European Lung Cancer Congress (ELCC) 2024
which took place in Prague, Czech Republic, including the EVOKE-02, IMscin002,
FLAURA2, MARIPOSA-2 and PAPILLON clinical trials. Hear from Federico Cappuzzo, AUSL
della Romagna-Ravenna, Ravenna, Italy, Natalia Valdiviezo, Instituto Nacional de
Enfermedades Neoplásicas, Lima, Peru, Alexander Spira, Next Oncology-Virginia VCS,
Joshua Sabari, NYU Langone Health, New York, NY, as they talk on exciting results in lung
cancer.

In today’s episode, we bring you key highlights from ESMO Breast 2024, diving into important discussions surrounding the latest research and clinical data regarding breast cancer. We bring insights from top field experts, set to enlighten you on new breakthroughs and developments, including updates from the DESTINY-Breast02 trial as well as first-line CDK4/6 inhibitor clinical data in HR+/HER2-advanced breast cancer.

The post Key Updates at ESMO Breast 2024 appeared first on VJOncology.

In today's episode, we bring you key highlights from ESMO Breast 2024, diving into important discussions surrounding the latest research and clinical data regarding breast cancer. We bring insights from top field experts, set to enlighten you on new breakthroughs and developments, including updates from the DESTINY-Breast02 trial as well as first-line CDK4/6 inhibitor clinical data in HR+/HER2-advanced breast cancer. 

In this podcast, we continue to commemorate Bladder Cancer Awareness Month in May with a special limited series, where we invite a special guest to discuss and share their expert perspectives within this ever evolving field. This week, Rob Jones, MD, PhD, University of Glasgow, Glasgow, UK, will be talking about first-line treatment paradigms in bladder cancer, survivorship challenges, and the current state of bladder cancer treatment in the UK. 

The post Bladder Cancer Awareness Month Part II: Management of UC in the UK appeared first on VJOncology.

In this podcast, we continue to commemorate Bladder Cancer Awareness Month in
May with a special limited series, where we invite a special guest to
discuss and share their expert perspectives within this ever evolving field.
This week, Rob Jones, MD, PhD, University of Glasgow, Glasgow, UK, will be talking about first-line treatment paradigms in bladder cancer, survivorship challenges, and the current state of bladder cancer treatment in the UK. 

In this podcast, we commemorate Bladder Cancer Awareness Month in May with a special limited series, where we invite a special guest to discuss and share their expert perspectives within this ever evolving field. This week, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, will be talking about antibody-drug conjugates, which have made a big impact in the treatment landscape of bladder cancer and other solid tumors. He will provide his thoughts on the approval of enfortumab vedotin, managing toxicities, and the future of ADCs.

The post Bladder Cancer Awareness Month Part I: The...

In this podcast, we commemorate Bladder Cancer Awareness Month in
May with a special limited series, where we invite a special guest to
discuss and share their expert perspectives within this ever evolving field.
This week, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer
Center, New York, NY, will be talking about antibody-drug conjugates,
which have made a big impact in the treatment landscape of bladder
cancer and other solid tumors. He will provide his thoughts on the
approval of enfortumab vedotin, managing toxicities, and the future of
ADCs